Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABI-H3733 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABI-H3733 | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABI-H3733 | DRUG | 25 mg or 100 mg tablets for oral administration |
| Placebo | DRUG | 25 mg or 100 mg tablets for oral administration |
Inclusion Criteria: 1. Body mass index (BMI) ≥ 18.0 and \< 35.0 kg/m(2), where BMI = weight (kg)/(height \[m\])(2) with a minimum body weight of 45 kg. 2. Chronic hepatitis B infection, defined as HBV infection for ≥6 months documented 3. Treatment-naïve or off-antiviral therapy for ≥24 weeks prior...
ABI-H3733 is an investigational small molecule being developed for the treatment of chronic Hepatitis B. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ABI-H3733 is being developed by Assembly Biosciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ASMB.
ABI-H3733 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational, meaning it is not yet approved for commercial use.
ABI-H3733 has one completed Phase 1 clinical trial, registered as NCT05414981. This study assessed the safety, pharmacokinetics, and antiviral activity of ABI-H3733 in subjects with chronic Hepatitis B virus infection.
ABI-H3733 is a small molecule designed to treat chronic Hepatitis B. The specific molecular target has not been disclosed in the available information.